MedTrace Logo

A Study of Concomitant Camrelizumab With Chemoradiation for Locally Advanced Head and Neck Cancer

NCT04405154 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2020-05-28

No results posted yet for this study

Summary

The goal of this study is to determine the efficacy and safety of camrelizumab given concomitantly with chemoradiation in participants with unresectable, locally advanced head and neck squamous cell carcinoma (LA-HNSCC). All participants will receive camrelizumab in addition to chemoradiation, the standard treatment for LA-HNSCC.

Conditions

  • Head and Neck Neoplasms

Interventions

BIOLOGICAL

Camrelizumab

Administered as an intravenous (IV) infusion every 2 weeks (Q2W): 14 days prior to radiation, then Day 1 of radiation and then every 14 days for total 8 doses.

DRUG

Cisplatin

75-100 mg/m\^2 administered as an IV infusion Q3W, for a total of 3 doses, at the same time as radiation: Day 1, Day 22, Day 43 of radiation.

RADIATION

IMRT or VMAT

66-70 Gy given in 33-35 fractions over 6-7 weeks.

Sponsors & Collaborators

  • West China Hospital

    lead OTHER

Principal Investigators

  • Yan Li, MD,PhD · West China Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-01
Primary Completion
2023-05-31
Completion
2025-05-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04405154 on ClinicalTrials.gov